Pasireotide studies: 76 papers with results
Page 2 of 2
Pasireotide has 484 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.
- Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S · The Journal of clinical endocrinology and metabolism · 2010
Non-randomized trial · 4 results
- Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Pivonello R · Clinical endocrinology · 2014
Non-randomized trial · 5 results
- A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.
Golor G · Drug design, development and therapy · 2012
Non-randomized trial · 8 results
- A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Bauman JE · Cancers · 2022
Non-randomized trial · 3 results
- Pharmacokinetics and Safety of Long-Acting Release Formulations of Pasireotide (SOM230) in a Male Population Who Are Hyperendemic Hepatitis B/C and Chronic Kidney Disease: An Open-Label, Phase I Study.
Huang CJ · European journal of drug metabolism and pharmacokinetics · 2023
Non-randomized trial · 2 results
- Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.
Webb SM · European journal of endocrinology · 2014
Observational study · 9 results
- Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.
Nedelman J · Clinical pharmacokinetics · 2018
Observational study · 7 results
- Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Duluc C · EMBO molecular medicine · 2015
Animal study (in vivo) · mouse · 7 results
- Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Hopp K · Journal of the American Society of Nephrology : JASN · 2015
Animal study (in vivo) · mouse · 2 results
- Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV · Hepatology (Baltimore, Md.) · 2013
Animal study (in vivo) · rat and mouse · 6 results
- Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA · The Journal of endocrinology · 2012
Animal study (in vivo) · rat · 6 results
- Activation of somatostatin receptors attenuates pulmonary fibrosis.
Borie R · Thorax · 2008
Animal study (in vivo) · mouse · 11 results
- The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
Batista DL · The Journal of clinical endocrinology and metabolism · 2006
In vitro (cells) · 2 results
- Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R · The Journal of clinical endocrinology and metabolism · 2013
In vitro (cells) · 2 results
- Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S · The Journal of clinical endocrinology and metabolism · 2009
In vitro (cells) · 12 results
- Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC · Endocrine-related cancer · 2007
In vitro (cells) · 6 results
- Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.
Pöll F · Molecular endocrinology (Baltimore, Md.) · 2010
In vitro (cells) · 9 results
- Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A · The Journal of endocrinology · 2016
In vitro (cells) · 6 results
- Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A · The Journal of clinical endocrinology and metabolism · 2009
In vitro (cells) · mouse · 9 results
- TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV · Hepatology (Baltimore, Md.) · 2017
In vitro (cells) · 1 result
- Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness.
Marques P · Endocrine-related cancer · 2019
In vitro (cells) · 2 results
- In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F · The Journal of clinical endocrinology and metabolism · 2017
In vitro (cells) · 6 results
- Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
Zatelli MC · Endocrine-related cancer · 2010
In vitro (cells) · 3 results
- GHRH excess and blockade in X-LAG syndrome.
Daly AF · Endocrine-related cancer · 2016
In vitro (cells) · 1 result
- Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A · Endocrine-related cancer · 2014
In vitro (cells) · 5 results
- Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.
Pasquali D · Journal of molecular endocrinology · 2008
In vitro (cells) · 8 results